News
-
-
-
COMMUNIQUÉ DE PRESSE
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q4 revenues of $1.0B with a net loss of $(1.1)B. Forecasts 2025 revenue of $1.5-2.5B. Submitted 3 mRNA products for regulatory approval. Financial details and pipeline updates disclosed -
-
-
COMMUNIQUÉ DE PRESSE
Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025
Moderna, Inc. to host conference call on February 14, 2025 to report Q4 and full year 2024 financial results, and provide a corporate update. Details on webcast available on Moderna website -
-
-
COMMUNIQUÉ DE PRESSE
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
Moderna awarded tender to supply mRNA COVID-19 vaccine in EU, Norway, and North Macedonia, offering diverse formats like prefilled syringes. Enhancing vaccination campaigns with efficient options -
